FDA Brief

Warning letters Drugs

FDA warning letter to

Kleenhanz, LLC

High riskIssued Apr 19, 2022Posted Apr 21, 2022Center for Drug Evaluation and Research | CDER

FDA told Kleenhanz its antiseptic towelettes were unapproved drugs because the website and Twitter claimed they fight COVID-19 and other diseases.

What happened

FDA reviewed the Kleenhanz website (www.kleenhanz.com) and its Twitter page in April 2022; the site sends shoppers to retailers such as Amazon to buy the products. FDA found claims that the Kleenhanz Towelettes protect against coronavirus and kill HIV, hepatitis B and C, herpes, MRSA, E. coli and many other organisms. FDA said this makes the towelettes unapproved new drugs (a drug sold without the FDA approval the law requires) and misbranded drugs (labeled or promoted in ways that break the law).

What FDA found

  1. The towelettes are sold as drugs to prevent or treat disease without an FDA-approved application.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded because they are nonprescription drugs that do not meet the requirements for marketing without an approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. § 352(ee)
  3. The website and Twitter posts claim the wipes prevent COVID-19 and other infections, which is evidence of intended drug use.

    21 CFR 201.128
  4. The label names only benzalkonium chloride as the active ingredient, but the website says the wipes also contain benzethonium chloride, which is not allowed in consumer antiseptic hand rubs.

    21 CFR 201.66(b)(2); 1994 Tentative Final Monograph
  5. Using more than one active ingredient does not match the monograph rules for consumer or health care antiseptics, so the products do not qualify for marketing without approval.

    Section 505G(a)(3) of the FD&C Act, 21 U.S.C. § 355h
  6. Shipping these unapproved, misbranded products between states is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. §§ 331(a) and (d)

What FDA wants

FDA tells the company to stop selling the unapproved products immediately, review all websites, labels and promotional material, and email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours describing the steps taken and how repeat violations will be prevented, with supporting documents. If complete correction within 48 hours is not possible, the company must explain the delay and give a date.

Who should pay attention

  • retailers and online marketplaces that list antiseptic wipes
  • brands and contract manufacturers of hand sanitizer and antiseptic wipes
  • e-commerce sellers whose product pages make germ- or disease-killing claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk